New Therapy Improves Outcomes for Early-Stage Lung Cancer Patients

A phase III clinical trial, LIBRETTO-432, has demonstrated that adjuvant selpercatinib significantly enhances event-free survival in individuals with early-stage RET fusion-positive non-small cell lung cancer. Presented at the ASCO Annual Meeting, these findings are considered to be immediately transformative for current treatment practices in this specific patient group.